Satellite symposia are non-commercial, grant-funded learning activities that are planned and conducted by the corporate community in conjunction with Nexus 2025. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.
Registration, content, and continuing education are the sole responsibility of the provider. There is no fee for pre-registering for these educational activities, as registration is for planning purposes only.
Location: National Harbor 2
- Provider: MedscapeLive
- Supported by: Cytokinetics
- Continuing education: Pharmacists
- Contact hours: 1.5
Program Description:
Join us for a dynamic symposium designed specifically for pharmacists to sharpen their expertise in managing hypertrophic cardiomyopathy (HCM). This event features rapid-fire updates from top experts on the latest clinical data, mechanisms of action, and the evolving role of pharmacists in optimizing cardiac myosin inhibitor (CMI) therapy. Through engaging case-based discussions, you'll explore real-world strategies for improving adherence, navigating access barriers, and personalizing treatment. Don't miss this opportunity to elevate your clinical impact and confidently apply cutting-edge HCM management approaches in your practice. Gain the knowledge and tools to lead in this rapidly advancing therapeutic space.
Learning Objectives:
Have increased knowledge regarding the:
- Mechanism of action (MOA) and clinical benefits of CMIs in HCM management.
- Recent clinical trial data on CMIs to inform therapeutic decisions.
Have greater competence related to:
- Strategies for pharmacists to optimize the implementation and adherence of CMI therapy
- Evidence-based approaches to manage HCM patients using real-world case studies
Program Manager:
Griseldis Ortega
MedscapeLive
gortega@medscapelive.com
Location: National Harbor 10
- Provider: Pharmacy Times Continuing Education
- Supported by: Genentech, a member of the Roche Group
- Continuing education: Managed care, Pharmacists
- Contact hours: 1.5
Program Description:
Neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), diabetic macular edema (DME), and retinal vein occlusion (RVO) are all retinal diseases that have similar pathology involving inflammation and leakage. nAMD occurs when an upregulation of inflammatory cytokines in the retina and choroid leads to the growth of leaky abnormal blood vessels, often resulting in swelling and fibrosis. DR occurs as a complication of diabetes, where damage to blood vessels causes blood and fluid to leak into the retina. It can lead to DME, where the fluid will leak and cause damage inside the macula. Similarly, RVO can manifest to different degrees based on a patient’s history of pre-existing arterial disease. Intravitreal VEGF inhibitors are the most effective treatment for these eye diseases, decreasing the growth of abnormal blood vessels and reducing leakage in the retina. While these treatments are effective, they present unique challenges that contribute to the overall disease burden for patients. Frequent injection appointments, limited access, adverse effects, and high treatment costs hinder adherence rates, leading to increased health care utilization. Managed care pharmacists play a key role in evaluating new and emerging therapies that offer greater durability, reduce treatment burden, and improve patient quality of life. This activity will add to that effort by highlighting real-world data and updates from recent conferences, addressing the challenges patients face when undergoing therapy for retinal diseases, and presenting strategies to apply clinical evidence in managed care decision-making to optimize outcomes, costs, and access to care.
Learning Objectives:
- Identify the clinical and economic burden of certain exudative retinal diseases and key challenges faced by patients and caregivers to inform managed care decision-making.
- Break down the clinical data and real-world evidence for current and emerging anti-VEGF and anti-Ang-2 treatments for retinal disease.
- Employ evidence-based guidelines and real-world evidence to optimize treatment strategies for retinal diseases that balance efficacy, cost-effectiveness, and patient access within managed care settings.
Program Manager:
Victoria Chirdo
Pharmacy Times Continuing Education
vchirdo@mjhlifesciences.com
Location: National Harbor 11
- Provider: Pharmacy Times Continuing Education
- Supported by: Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
- Continuing education: Managed care, Pharmacists
- Contact hours: 1.5
Program Description:
Cardiovascular-kidney-metabolic (CKM) syndrome is a progressive, multi-system condition characterized by the coexistence of chronic kidney disease, metabolic dysfunction, and cardiovascular disease. With overlapping pathophysiology and compounding risks, CKM poses significant challenges in treatment selection, particularly when patients present with both cardiac and renal comorbidities. Sodium glucose cotransporter 2 (SGLT2) inhibitors have emerged as a cornerstone of therapy, demonstrating efficacy across glucose management, cardiovascular outcomes, and renal protection. However, with multiple agents available and variable data across patient populations, selecting the most appropriate treatment can be complex. This discussion will examine the latest clinical data on SGLT2 inhibitors, including their impact on disease progression, hospitalization, and mortality. It will also address the nuances of choosing therapy in patients with overlapping conditions and explore guideline-directed treatment strategies supported by real-world evidence. A case-based discussion will be included to illustrate how pharmacists can evaluate available options and advocate for access to cost-effective, evidence-based care that supports improved patient outcomes and system-wide value.
Learning Objectives:
- Explain cardiovascular-kidney-metabolic (CKM) syndrome and the importance of early identification, diagnosis, and prompt treatment to improve prognosis, including slowing the disease process and reducing complications.
- Apply the guideline recommendations for CKM syndrome, including heart failure and chronic kidney disease, and the data supporting the use of SGLT2 inhibitors in the care of patients with cardiorenal syndrome with or without diabetes.
- Determine an individualized treatment strategy integrating best practices using SGLT2 inhibitors for patients with CKM syndrome to promote quality care while efficiently allocating health care resources.
Program Manager:
Victoria Chirdo
Pharmacy Times Continuing Education
vchirdo@mjhlifesciences.com
Location: National Harbor 2
- Provider: MedscapeLive
- Supported by: Abbott Diabetes Care
- Continuing education: Pharmacists
- Contact hours: 1.5
Program Description:
Join us for a lively, quiz show-style symposium on the latest technology to monitor and manage patients with diabetes. During this interactive, 60-minute program, experts will test your knowledge and review various aspects of care for patients with diabetes, including updates in quality and safety metrics, formulary and medical utilization management, as well as affordability in practice. We look forward to seeing you there!
Learning Objectives:
Upon completion of this activity, participants will:
Have increased knowledge regarding the
- Updated quality metrics related to successful diabetes management.
- Data supporting the role and use of continuous glucose monitoring in patients with type 2 diabetes.
- Updates in the roles of automated insulin delivery and continuous ketone monitoring in patients with diabetes from a payer perspective.
Demonstrate greater confidence in their ability to:
- Appreciate the value of new technologies for diabetes assessment and monitoring.
Manager, Program Management
Griseldis Ortega
MedscapeLive
gortega@medscapelive.com
Location: National Harbor 10
- Provider: Pharmacy Times Continuing Education
- Supported by: Alnylam
- Continuing education: Managed care, Pharmacists
- Contact Hours: 1.5
Program Description:
Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a progressive condition caused by the misfolding of the transthyretin (TTR) protein, which aggregates into amyloid fibrils that deposit in tissues and organs, such as the heart, impairing their function and structural integrity. Although often underdiagnosed due to nonspecific symptoms and overlap with other conditions, ATTR-CM has become more manageable with the growing number of FDA-approved disease-modifying therapies (DMTs). Managed care pharmacists play a critical role in navigating the expanding therapeutic landscape by supporting the development of clinical guidelines to facilitate evidence-based treatment selection, evaluate cost-effectiveness, ensure timely patient access, and make formulary decisions aligned with current recommendations. This session will provide an in-depth review of diagnostic strategies, current and emerging therapies, and clinical guidelines in ATTR-CM to help pharmacists make informed treatment and management decisions. With a greater understanding of diagnostic tools, available therapies, and current clinical guidance, managed care professionals and pharmacists will be better equipped to support timely, appropriate therapy selection and improve patients’ overall quality of life.
Learning Objectives:
- Examine the burden of transthyretin amyloidosis cardiomyopathy (ATTR-CM) focusing on aspects such as patient quality of life, frequency of misdiagnosis, and the extent of health care resource use.
- Investigate current and emerging disease-modifying therapies for ATTR-CM by reviewing clinical guidelines, mechanisms of action, dosing strategies, administration considerations, and safety profiles.
- Determine strategies to address the burden of high health care utilization in ATTR-CM by enhancing multidisciplinary care coordination and improving patient access to appropriate therapies within managed care settings.
Program Manager:
Victoria Chirdo
Pharmacy Times Continuing Education
vchirdo@mjhlifesciences.com
Location: National Harbor 11
- Provider: Pharmacy Times Continuing Education
- Supported by: AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA
- Continuing education: Managed care, Oncology pharmacists
- Contact hours: 1.5
Program Description:
Navigating the complex and rapidly evolving treatment landscape for prostate cancer presents significant challenges for managed care and oncology pharmacists. The disease is characterized by a wide range of prognoses, from indolent to highly aggressive, and is further complicated by significant disparities in diagnoses. From a managed care perspective, balancing the high cost of novel therapies against the need to provide timely access to effective, personalized care may present unique challenges. This session will review the latest therapeutic advancements in prostate cancer, with a focus on optimizing patient care and outcomes. Speakers will discuss the evolving role of second-generation anti-androgens, PARP inhibitors, and the use of molecular testing to personalize therapy. A key focus will be the role of the managed care pharmacist through an examination of the cost-effectiveness of advanced prostate cancer therapies and strategies to ensure equitable access and optimize therapeutic outcomes.
Learning Objectives:
- Investigate the evolving treatment landscape for prostate cancer, including the role of second-generation anti-androgens, PARP inhibitors, and the use of molecular testing in personalizing therapy to optimize patient outcomes.
- Examine the latest clinical and safety evidence for new and emerging anti-androgens, PARPi, and PARPi/anti-androgen combinations used to treat prostate cancer.
- Compare the cost-effectiveness of advanced prostate cancer treatments and strategies to optimize therapeutic access and outcomes in managed care settings.
Program Manager:
Victoria Chirdo
Pharmacy Times Continuing Education
vchirdo@mjhlifesciences.com
For more information, please contact us.